Cotellic (cobimetinib)

News alerts, weekly reports and conference planners

Company:

Exelixis, Roche

Drug class:

MEK1 inhibitor

Related drugs:

BRAF V600	Melanoma	BRAF V600	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: A2 - Guideline atezolizumab + vemurafenib + cobimetinib Sensitive : A2	atezolizumab + vemurafenib + cobimetinib Sensitive: A2 - Guideline atezolizumab + vemurafenib + cobimetinib Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
BRAF V600E	Astrocytoma	BRAF V600E	Astrocytoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
BRAF V600E	Astrocytoma	BRAF V600E	Astrocytoma	cobimetinib Sensitive: A2 - Guideline cobimetinib Sensitive : A2	cobimetinib Sensitive: A2 - Guideline cobimetinib Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	cobimetinib Sensitive: A2 - Guideline cobimetinib Sensitive : A2	cobimetinib Sensitive: A2 - Guideline cobimetinib Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	atezolizumab + cobimetinib Resistant: A2 - Guideline atezolizumab + cobimetinib Resistant : A2	atezolizumab + cobimetinib Resistant: A2 - Guideline atezolizumab + cobimetinib Resistant : A2
BRAF V600E	Glioblastoma	BRAF V600E	Glioblastoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
IDH2 mutation + BRAF V600E	Astrocytoma	IDH2 mutation + BRAF V600E	Astrocytoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
IDH1 mutation + BRAF V600E	Astrocytoma	IDH1 mutation + BRAF V600E	Astrocytoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
TMB-H	Melanoma	TMB-H	Melanoma	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B
TMB-H	Melanoma	TMB-H	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B
TMB-H + PD-L1 negative	Melanoma	TMB-H + PD-L1 negative	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B
LDHA-L + PD-L1 expression	Melanoma	LDHA-L + PD-L1 expression	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B
LDHB-L + PD-L1 expression	Melanoma	LDHB-L + PD-L1 expression	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B
PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B
AKT1 mutation	Colorectal Cancer	AKT1 mutation	Colorectal Cancer	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B
TMB-L + LDH elevation	Melanoma	TMB-L + LDH elevation	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B
High IFNG gene signature	Melanoma	High IFNG gene signature	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B
TMB-H + LDH elevation	Melanoma	TMB-H + LDH elevation	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B
BRAF V600 + LDH elevation + PD-L1 negative	Melanoma	BRAF V600 + LDH elevation + PD-L1 negative	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B
BRAF V600	Ganglioglioma	BRAF V600	Ganglioglioma	vemurafenib + cobimetinib Sensitive: C1 - Off-label vemurafenib + cobimetinib Sensitive : C1	vemurafenib + cobimetinib Sensitive: C1 - Off-label vemurafenib + cobimetinib Sensitive : C1
BRAF V600	Glioma	BRAF V600	Glioma	vemurafenib + cobimetinib Sensitive: C1 - Off-label vemurafenib + cobimetinib Sensitive : C1	vemurafenib + cobimetinib Sensitive: C1 - Off-label vemurafenib + cobimetinib Sensitive : C1
BRAF V600E	Multiple Myeloma	BRAF V600E	Multiple Myeloma	vemurafenib + cobimetinib Sensitive: C1 - Off-label vemurafenib + cobimetinib Sensitive : C1	vemurafenib + cobimetinib Sensitive: C1 - Off-label vemurafenib + cobimetinib Sensitive : C1
BRAF V600	Thyroid Gland Papillary Carcinoma	BRAF V600	Thyroid Gland Papillary Carcinoma	vemurafenib + cobimetinib Sensitive: C1 - Off-label vemurafenib + cobimetinib Sensitive : C1	vemurafenib + cobimetinib Sensitive: C1 - Off-label vemurafenib + cobimetinib Sensitive : C1

Cotellic (cobimetinib)

Associations
(94)

Associations
(94)

Cotellic (cobimetinib)

Associations(94)

Associations(94)

Associations
(94)

Associations
(94)